Cencora (ABG) Price & Analysis

1 Followers

ABG Stock Chart & Stats

€287.10

€5.10(1.96%)

At close: Jul 24 4:00 PM EDT

€287.10

€5.10(1.96%)

Day’s Range― - ―

52-Week Range€212.90 - €325.25

Previous CloseN/A

Volume0.00

Average Volume (3M)4.00

Market Cap

€56.34B

Enterprise Value€63.93B

Total Cash (Recent Filing)€2.82B

Total Debt (Recent Filing)€11.72B

Price to Earnings (P/E)24.5

Beta0.06

Next Earnings

Nov 04, 2026

EPS Estimate

4.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)13.52

Shares Outstanding190,827,160

10 Day Avg. Volume8

30 Day Avg. Volume4

Financial Highlights & Ratios

PEG Ratio7.05

Price to Book (P/B)40.17

Price to Sales (P/S)0.19

P/FCF Ratio18.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€333.10

Price Target Upside16.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)17.67

Revenue Forecast (FY)€315.14B

Bulls Say, Bears Say

Bulls Say

Strong Cash GenerationCencora’s substantial free cash flow provides recurring internal funding for debt service, reinvestment, acquisitions, and shareholder returns. The absolute cash generation improves financial resilience and gives management flexibility to support growth initiatives without relying entirely on external financing.

Specialty-driven Operating GrowthSpecialty pharmaceuticals, oncology services, and related healthcare solutions are producing stronger growth and operating leverage than the underlying distribution model alone. This mix shift can support earnings durability by expanding higher-value services and deepening relationships with providers and manufacturers.

Expansion In Community OncologyThe AON transaction would broaden Cencora’s oncology platform, add access to more physician practices, and strengthen its integrated support model in community cancer care. Management expects the acquisition to be adjusted-EPS accretive in the second year, indicating a potentially durable strategic growth contribution.

Bears Say

Elevated LeverageHigh leverage relative to equity leaves Cencora more sensitive to working-capital movements, financing costs, and execution setbacks. Although equity has rebuilt and cash flow is strong, the historical negative equity and elevated debt burden reduce flexibility for future acquisitions or an operating downturn.

Structurally Thin MarginsCencora’s distribution-heavy model operates with limited margin protection, so modest pricing, volume, or product-mix pressure can materially affect earnings. Thin profitability constrains resilience and makes sustained operating improvement important for absorbing cost inflation, customer changes, or manufacturer economics.

Manufacturer Pricing PressureLarge manufacturer price reductions can suppress reported revenue and challenge the economics of pharmaceutical distribution, particularly when the business earns relatively thin margins. Continued pricing actions could make growth harder to convert into profit and increase reliance on specialty mix and operating execution.

Cencora News

Cencora price target raised to $377 from $346 at Morgan Stanley

Morgan Stanley raised the firm’s price target on Cencora (COR) to $377 from $346 and keeps an Overweight...

2d ago

COR

Midday Fly By: Meta, Tesla slipping after quarterly reports

The major averages were broadly lower near noon amid renewed concerns over AI spending and an increase in...

10d ago

BMI

COR

Cencora price target raised to $345 from $330 at BofA

BofA raised the firm’s price target on Cencora (COR) to $345 from $330 and keeps a Neutral rating...

10d ago

COR

Cencora sees FY26 adjusted EPS to be at least $17.90

Cencora (COR) last night updated its FY26 financial guidance to reflect the strength of the U.S. Healthcare Solutions...

10d ago

COR

Cencora price target raised to $375 from $373 at Baird

Baird raised the firm’s price target on Cencora (COR) to $375 from $373 and keeps an Outperform rating...

10d ago

COR

Cencora to acquire American Oncology Network in $2.4B transaction

Cencora (COR) has signed a definitive agreement to acquire American Oncology Network (AONC), a physician-led network of more...

11d ago

COR

AONC

Cencora price target raised to $380 from $340 at Argus

Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $380 from $340 and keeps...

12d ago

COR

Cencora price target lowered to $400 from $430 at UBS

UBS lowered the firm’s price target on Cencora (COR) to $400 from $430 and keeps a Buy rating...

16d ago

COR

Cencora to Acquire American Oncology Network in Expansion

An update from Cencora ( ($COR) ) is now available. On October 21, 2026, Cencora announced a definitive...

11d ago

COR

Insider Moves in PIMCO, Strive, Cencora, Grace, Banco Bradesco

Insiders have been trading these 5 stocks: (($PDI)), (($ASST)), (($COR)), (($GRCE)) and (($BBD)). Here is a breakdown of...

22d ago

BBD

COR

Cencora Adds Independent Director to Support Growth Strategy

An update from Cencora ( ($COR) ) is now available. On September 24, 2026, Cencora’s Board of Directors...

1M ago

COR

Cencora appoints Robert Sanchez to board of directors

Cencora (COR) announced that its Board of Directors has elected Robert Sanchez as a new independent director, effective...

1M ago

COR

Cencora sees ‘wraparound’ impact in 2027 from Walgreens

Says Walgreens “has been an important strategic partner for us over a long period of time. We have...

2M ago

COR

Cencora Announces Resignation of Board Member Lorence Kim

An update from Cencora ( ($COR) ) is now available. On August 13, 2026, Cencora, Inc. announced that...

3M ago

COR

ABG FAQ

What was Cencora’s price range in the past 12 months?

Cencora lowest stock price was €212.90 and its highest was €325.25 in the past 12 months.

What is Cencora’s market cap?

Cencora’s market cap is €56.34B.

When is Cencora’s upcoming earnings report date?

Cencora’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.

How were Cencora’s earnings last quarter?

Cencora released its earnings results on Aug 05, 2026. The company reported €3.998 earnings per share for the quarter, beating the consensus estimate of €3.879 by €0.119.

Is Cencora overvalued?

According to Wall Street analysts Cencora’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cencora pay dividends?

Cencora does not currently pay dividends.

What is Cencora’s EPS estimate?

Cencora’s EPS estimate is 4.08.

How many shares outstanding does Cencora have?

Cencora has 190,827,160 shares outstanding.

What happened to Cencora’s price movement after its last earnings report?

Cencora reported an EPS of €3.998 in its last earnings report, beating expectations of €3.879. Following the earnings report the stock price went down -0.904%.

Which hedge fund is a major shareholder of Cencora?

Currently, no hedge funds are holding shares in DE:ABG

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cencora Stock Smart Score

Outperform

Fundamentals

Return on Equity

106.43%

Trailing 12-Months

Asset Growth

13.32%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Cencora

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Cencora (ABG) Earnings & Revenues

Historic Earnings Reports

ABG Company Deck

ABG Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call emphasized strong execution and durable specialty-driven growth: consolidated revenue and adjusted gross profit growth, margin expansion, double-digit operating income increases, 12% EPS growth, upgraded EPS guidance, significant share repurchases, and robust free cash flow. Key drivers included strong U.S. Healthcare Solutions performance (MSOs and specialty), International momentum, and OneOncology outperforming expectations. Headwinds discussed were notable but largely manageable: $2.4B of manufacturer list-price reductions, a prior oncology customer loss, lower mail-order sales, acquisition-related higher operating expenses and increased interest expense, and a potential FY27 earnings headwind from the planned MWI transaction. Overall, the positive operational and financial outcomes and guidance raise outweigh the discrete and partly acquisition-related challenges.View all DE:ABG earnings summaries

ABG Revenue Breakdown

90.55% U.S. Healthcare Solutions

9.45% International Healthcare Solutions

>-0.01% Intersegment eliminations

ABG Stock 12 Month Forecast

Average Price Target

€333.10

▲(16.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"227":"€227","358":"€358","259.75":"€259.8","292.5":"€292.5","325.25":"€325.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":357.139988,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€357.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":333.1017195769231,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€333.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":294.6404901,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€294.64</span>\n  </div></div>","useHTML":true}}],"tickPositions":[227,259.75,292.5,325.25,358],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,262.8,270.0569221538462,277.3138443076923,284.5707664615385,291.8276886153846,299.0846107692308,306.34153292307695,313.5984550769231,320.85537723076925,328.1122993846154,335.36922153846155,342.6261436923077,349.88306584615384,{"y":357.139988,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,262.8,268.20782458284026,273.6156491656805,279.0234737485207,284.43129833136095,289.8391229142012,295.24694749704145,300.65477207988164,306.0625966627219,311.47042124556214,316.8782458284024,322.2860704112426,327.6938949940828,{"y":333.1017195769231,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,262.8,265.2492684692308,267.69853693846153,270.1478054076923,272.5970738769231,275.04634234615384,277.4956108153846,279.9448792846154,282.3941477538462,284.84341622307693,287.2926846923077,289.7419531615385,292.19122163076923,{"y":294.6404901,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":265.531,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.632,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":311.087,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":287.478,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.617,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":315.138,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":267.793,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":263.163,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":228.46,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.128,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.184,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.8,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >